Cantor Fitzgerald, L. P. Adverum Biotechnologies, Inc. Transaction History

Cantor Fitzgerald, L. P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.75 - $1.26 $3,508 - $5,894	-4,678 Reduced 2.87%	158,160 $118,000
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.59 $13,600 - $31,800	20,000 Added 14.0%	162,838 $258,000
Q1 2023 May 15, 2023	BUY	$0.62 - $0.85 $4,859 - $6,662	7,838 Added 5.81%	142,838 $102,000
Q4 2022 Feb 14, 2023	BUY	$0.54 - $10.3 $62,100 - $1.18 Million	115,000 Added 575.0%	135,000 $78,000
Q3 2022 Nov 14, 2022	BUY	$0.96 - $9.68 $19,200 - $193,600	20,000 New	20,000 $19,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Cantor Fitzgerald, L. P., based on Form 13F filings with the SEC.

Stay updated on Cantor Fitzgerald, L. P. with notifications on news.